DE3344891C2 - - Google Patents
Info
- Publication number
- DE3344891C2 DE3344891C2 DE3344891A DE3344891A DE3344891C2 DE 3344891 C2 DE3344891 C2 DE 3344891C2 DE 3344891 A DE3344891 A DE 3344891A DE 3344891 A DE3344891 A DE 3344891A DE 3344891 C2 DE3344891 C2 DE 3344891C2
- Authority
- DE
- Germany
- Prior art keywords
- binifibrate
- treatment
- deformability
- chlorophenoxy
- isobutyrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 3
- BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 description 9
- 229950004495 binifibrate Drugs 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 206010022562 Intermittent claudication Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- -1 trihydroxy propyl Chemical group 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT24965/82A IT1155447B (it) | 1982-12-23 | 1982-12-23 | Composizione farmaceutiche contenenti binifibrato e loro uso terapeutico |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3344891A1 DE3344891A1 (de) | 1984-06-28 |
| DE3344891C2 true DE3344891C2 (esLanguage) | 1987-10-15 |
Family
ID=11215279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19833344891 Granted DE3344891A1 (de) | 1982-12-23 | 1983-12-12 | Verwendung von trihydroxypropyl-2-p-chlorphenoxyisobutyrat-1, 3-dinicotinat zur behandlung von krankheitszustaenden, die durch ungenuegende herz-, gehirn- oder periphere durchblutung verursacht werden |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS59118707A (esLanguage) |
| DE (1) | DE3344891A1 (esLanguage) |
| IT (1) | IT1155447B (esLanguage) |
-
1982
- 1982-12-23 IT IT24965/82A patent/IT1155447B/it active
-
1983
- 1983-12-12 DE DE19833344891 patent/DE3344891A1/de active Granted
- 1983-12-15 JP JP58237756A patent/JPS59118707A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT1155447B (it) | 1987-01-28 |
| DE3344891A1 (de) | 1984-06-28 |
| JPS59118707A (ja) | 1984-07-09 |
| JPH0340011B2 (esLanguage) | 1991-06-17 |
| IT8224965A0 (it) | 1982-12-23 |
| IT8224965A1 (it) | 1984-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1670827B2 (de) | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-di carbmethoxy-1,4-dihydropyridin | |
| EP0800827A1 (de) | Regelung der Reaktivität von humanen Blutplättchen durch Verabreichung eines Extrakts der Strandkiefer (Pycnogenol TM) | |
| DE3786893T2 (de) | Piperidinderivat zur Schmerzbehandlung. | |
| DE3390419T1 (de) | Arzneimittel zur Behandlung der Ulkuskrankheit | |
| DE3319282C2 (esLanguage) | ||
| DE2850483C2 (esLanguage) | ||
| DE2824165A1 (de) | Arzneimittel mit angstneurosen und angstaehnliche neurosen beseitigender wirkung und verfahren zum zubereiten des arzneimittels | |
| DE2040578A1 (de) | Neue Medikamente auf der Grundlage von Monoamiden von cyclischen Dicarbonsaeuren,insbesondere der Phthalsaeure,und Verfahren zu deren Herstellung | |
| DE2304284C2 (de) | 1,1-Diphenyläthylen-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE3344891C2 (esLanguage) | ||
| DE2542794C2 (de) | Molekülverbindungen aus Allantoin und Salzen der 2-Pyrrolidon-5-carbonsäure sowie Verfahren zu ihrer Herstellung | |
| DE1915497A1 (de) | Arzneimittel mit hypolipidaemischer und hypocholesterinaemischer Wirksamkeit | |
| DE2609746A1 (de) | Piperazinverbindungen sowie arzneimittel, die diese verbindungen enthalten | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| DE2502156C2 (de) | Thromboseverhütung und Hemmung von Blutplättchen-Aggregation | |
| DE1043587B (de) | Verfahren zur Herstellung eines Appetitzueglers | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE1792764C3 (de) | Coronarmittel | |
| DE69027577T2 (de) | Verwendung von Benzothiazepinen zur Herstellung von Arzneimitteln zur Behandlung von epileptischen Anfällen | |
| DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
| DE3305690A1 (de) | Glycerinmononitrate zur behandlung der angina pectoris | |
| DE3231571C2 (esLanguage) | ||
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| DE2828200A1 (de) | Verwendung von tetramisole oder levamisole oder deren salzen bei der bekaempfung von scabies (kraetze) | |
| DE3008335C2 (de) | 1-Aminoadamantan-D,L-2-acetamido-3-phenylpropionat, Verfahren zu seiner Herstellung und dieses Salz enthaltende pharmazeutische Zubereitungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |